Current Report Filing (8-k)
May 10 2023 - 4:28PM
Edgar (US Regulatory)
0001862150
false
0001862150
2023-05-09
2023-05-09
0001862150
CING:CommonStockParValue0.0001PerShareMember
2023-05-09
2023-05-09
0001862150
CING:WarrantsExercisableForOneShareOfCommonStockMember
2023-05-09
2023-05-09
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
May
9, 2023
CINGULATE
INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-40874 |
|
86-3825535 |
(State
or other jurisdiction |
|
(Commission |
|
(IRS
Employer |
of
incorporation) |
|
File
Number) |
|
Identification
No.) |
1901
W. 47th Place
Kansas City, KS 66205
(Address of principal executive offices) (Zip Code)
(913) 942-2300
(Registrant’s
telephone number, including area code)
(Former
name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
|
|
Securities
registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of exchange
on which registered |
Common Stock, par value $0.0001 per share |
|
CING |
|
The Nasdaq Stock Market LLC
(Nasdaq Capital Market) |
Warrants, exercisable for one share of common stock |
|
CINGW |
|
The Nasdaq Stock Market LLC
(Nasdaq Capital Market) |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
1.01. |
Entry
into a Material Definitive Agreement. |
As
previously disclosed, on August 9, 2022, Cingulate Therapeutics, LLC (“CTx”), a wholly owned subsidiary of Cingulate
Inc. (the “Company”), executed a $5.0 million promissory note (the “Original Note”) in favor of Werth Family
Investment Associates LLC (“WFIA”). On May 9, 2023, CTx executed an amended and restated promissory note (the
“Note”) in favor of WFIA that increased the principal amount of the Original Note from $5.0 million to $8.0 million.
WFIA owns 975,165 shares of the Company’s common stock and Peter J. Werth, a member of the Company’s Board of Directors
(the “Board”) and the manager of WFIA, owns 21,849 shares of the Company’s common stock.
The
Audit Committee and Board reviewed the terms of the Note pursuant to the Company’s Policy and Procedures for Related Person Transactions
and determined that the Note is in the best interests of the Company and its stockholders.
CTx
received the additional $3.0 million of principal under the Note from WFIA on May 9,
2023. Outstanding principal and all accrued and unpaid interest
is due and payable on August 8, 2025 unless accelerated due to an event of default. Beginning July 1, 2023, WFIA has the right during
the first five business days of each calendar quarter to demand payment of all outstanding principal and interest 120 days following
notice to CTx. CTx may prepay the Note, in whole or in part, without premium or penalty; provided, that no amount repaid may be reborrowed.
The
foregoing description of the Note does not purport to be complete and is qualified in its entirety by reference to the full text of the
Note, which has been filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item
2.02. |
Results
of Operations and Financial Condition. |
On
May 10, 2023,
the Company issued a press release announcing its financial results for the first quarter of 2023 and providing a clinical and business
update. A copy of the press release is furnished as Exhibit 99.1 and incorporated by reference.
Item
2.03. |
Creation
of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. |
The
information set forth in Item 1.01 is incorporated by reference into this Item 2.03.
Item 9.01. |
Financial Statements and Exhibits. |
(d)
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
CINGULATE
INC. |
|
|
|
Dated:
May 10, 2023 |
By: |
/s/
Louis G. Van Horn |
|
Name: |
Louis
G. Van Horn |
|
Title: |
Chief
Financial Officer |
Cingulate (NASDAQ:CING)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cingulate (NASDAQ:CING)
Historical Stock Chart
From Jul 2023 to Jul 2024